ClinicalTrials.gg
RecruitingNCT05571514NUTRANACREUpdated Oct 2, 2026

Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis

An interventional study of Mother-of-pearl and Calcium Carbonate in Post Menopausal Osteoporosis, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 7 sites in France. Open to female participants aged 50 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.
Updated Oct 2, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
50 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Osteoporosis, Postmenopausal with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Osteoporosis, Postmenopausal · France.

Planned enrollment
15th of 19
200 · median 719
Started
2023
with 1 other
No phase
2 of 22
2 open now
Registered
20th of 22
by date
Lead sponsor
1 of 22
Centre Hospitalier Universitaire de Saint Etienne

Among the 22 studies in Osteoporosis, Postmenopausal with a site in France, this one is the 15th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 with no phase, and was the 20th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

3 of the 22 studies in Osteoporosis, Postmenopausal with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Osteoporosis, Postmenopausal with a site in France, or all of them as a file.
02

Study summary

Post-menopausal osteoporosis and the resulting fractures are an important cause of disability and loss of independence. They also increase the risk of morbidity and mortality.

Given potential side effects, hormone replacement therapy is no longer recommended for menopausal women with risk of becoming osteoporotic. The very significant decrease in the use of these treatments is suspected of contributing to a resurgence in the incidence of osteoporotic fractures, particularly in women before the age of 70. There is a need for prevention of osteoporosis.

Read the detailed description

Mother-of-pearl is a candidate for long-term use due to the combination of its effects: calcium supplementation, anti-resorptive activity and osteoanabolic activity.

Our hypothesis is that powdered mother-of-pearl supplementation limits bone loss in postmenopausal women with risk of becoming osteoporotic.

03

Conditions studied

  • Post Menopausal Osteoporosis

Keywords

  • Mother-of-pearl
  • Osteoporosis
  • Ageing
  • Nutrition Health
  • Prevention
04

Who can participate

Ages eligible
50 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women (50-65y) with risk of becoming osteoporotic
  • T-score between -1 and -3
  • Absence of fragility fractures history

Exclusion criteria

Exclusion Criteria:

  • absence of parathyroid glands (phospho-calcic regulation)
  • presence of kidney stones
  • patients who follow a treatment that could interfere with bone metabolism (corticotherapy, menopausal hormonal therapy, anti-oestrogen treatment, non-controlled hyperthyroiditis, hyper- and hypothyroiditis)
  • bone diseases (Paget'disease, osteomalacia)
  • chronic alcoholism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Mother-of-pearl

    Patient randomized in the "Mother-of-pearl" group : Mother of pearl supplementation: 2 capsules of 400mg = 800mg mother of pearl/day, equivalent to 320mg Ca/day \- Vitamin D: 50,000 IU/month (standard practice)

    Dietary Supplement: Mother-of-pearl

  • Active comparator
    Calcium carbonate

    Patient randomized in the "Calcium carbonate" control group : Calcium carbonate supplementation: 2 capsules of 400mg= 800mg CaCO3/day, equivalent to 320mg Ca/day \- Vitamin D: 50,000 IU/month (standard practice)

    Dietary Supplement: Calcium Carbonate

Interventions

  • Dietary supplementMother-of-pearl

    The mother-of-pearl, derived from the inner shell of marine molluscs, is composed of calcium carbonate and organic compounds, some of which peptides are active on the bone. The mineralization inducing activity of the molecules extracted from the mother-of-pearl has been shown in vitro. Mother-of-pearl extract also contains molecules that inhibit the resorption activity of osteoclasts. Mother-of-pearl compounds can thus slow bone remodelling as showed in an ovariectomy-induced osteoporosis model in rat, where mother-of-pearl supplementation showed a better effect on limitation of bone loss than calcium carbonate supplementation.

  • Dietary supplementCalcium Carbonate

    Calcium carbonate is a source of calcium.

06

What researchers measure

Primary outcomes

  1. Change in bone loss at lumbar site

    Demonstrate that oral mother-of-pearl powder supplementation, for 1 year, reduces bone loss at lumbar site in postmenopausal women with risk of becoming osteoporotic, in a better way than oral supplementation with pure CaCO3. Measurement of the change in BMD will be performed by DXA (dual X-ray absorptiometry bone densitometry)

    Time frame: Baseline from 12 months

Secondary outcomes

  1. Tolerance to oral mother-of-pearl powder supplementation

    Tolerance will be assessed by collecting digestive disorders

    Time frame: Baseline from 12 months

  2. Change in bone loss at the upper end of the femur

    Evaluate the impact of oral mother-of-pearl powder supplementation, compared to oral supplementation with pure CaCO3, for 1 year, in postmenopausal women on the bone loss at the upper end of the femur Measurement of the change in BMD will be performed by DXA (dual X-ray absorptiometry bone densitometry)

    Time frame: Baseline from 12 months

  3. Change in bone remodeling of the femur

    Evaluate the impact of oral mother-of-pearl powder supplementation, compared to oral supplementation with pure CaCO3, for 1 year, in postmenopausal women on the bone remodeling Measurement of the change in BMD will be performed by measurement CTX (serum Collagen-telopeptide)

    Time frame: Baseline from 12 months

07

Study locations

1 of 7 sites recruiting
  • Hôpital Gabriel Montpied
    Clermont-Ferrand, France
    Not yet recruiting
    • Sandrine MALOCHET GUINAMAND, MD · Principal investigator
  • Clinique Universitaire de Rhumatologie
    Grenoble, France
    Not yet recruiting
    • Philippe GAUDIN, PhD · Principal investigator
  • CH Emile Roux
    Le Puy-en-Velay, France
    Not yet recruiting
    • Benjamin CASTAGNE, MD · Principal investigator
    • Adamah AMOUZOUGAN, MD · Sub investigator
  • Hôpital Edouard Herriot
    Lyon, France
    Not yet recruiting
    • Roland CHAPURLAT, PhD · Principal investigator
    • Mathilde PRORIOL, MD · Sub investigator
  • APHP - Hôpital Cochin
    Paris, 75014, France
    Not yet recruiting
    • Karine BRIOT, PhD · Principal investigator
  • CH Roanne
    Roanne, France
    Not yet recruiting
    • Mervyn MUNGROO, MD · Principal investigator
  • CHU Saint-Etienne
    Saint-Etienne, France
    Recruiting
    • Adamah AMOUZOUGAN, MD · Principal investigator
    • Thierry THOMAS, MD PhD · Sub investigator
    • Hubert MAROTTE, MD PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Nov 2027, 54 months after the start.

Of 48 non-industry interventional studies with no phase under Osteoporosis, Postmenopausal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 54 months is above that.

Counting every sponsor, half of 51 studies reached it within 17 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 7, 2022
StartActual
May 12, 2023
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • CHU Saint-Etienne · Saint-Etienne, France
Show 1 removed
  • CHU Saint-Etienne · Saint-Étienne, France
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    1 site added, 1 site removed
    Show site
    • CHU Saint-Etienne · Saint-Etienne, France
    Show 1 removed
    • CHU Saint-Etienne · Saint-Étienne, France
    + 5 other changes: verification date, responsible party, arm descriptions, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05571514
Responsible party
Sponsor
First posted
Oct 7, 2022
Start date
May 12, 2023
Primary completion
Nov 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Adamah AMOUZOUGAN, MD
Contact
amadah.amouzougan@chu-st-etienne.fr
(0)477120595 ext. +33
Florence RANCON, CRA
Contact
florence.rancon@chu-st-etienne.fr
(0)477829458 ext. +33
Adamah AMOUZOUGAN, MD
principal investigator · Centre Hospitalier Universitaire de Saint Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion